Compound ID | 4
Synonym(s): ACHN-490 | Zemdri | plazomicina | plazomicine
Class: Aminoglycoside
| Agent Type: | Semisynthetic; Small molecule; Direct acting; |
| Spectrum of activity: | Gram-positive & Gram-negative |
| Mechanism of action: | Protein synthesis inhibitor. Binds to the bacterial 30S ribosomal subunit to disrupt protein synthesis. |
| Target Pathogen: | Multidrug-resistant Enterobacterales (including Escherichia coli, Klebsiella pneumoniae, Enterobacter spp.); Pseudomonas aeruginosa and other Gram-negative pathogens; limited activity against Staphylococcus aureus including MRSA. |
| Propensity to select resistant mutants: | Moderate. Low frequency of resistance compared with older aminoglycosides due to engineered AME stability. |
| Description: | Semisynthetic derivative of sisomicin designed to overcome common aminoglycoside resistance mechanisms. FDA approved on 26 June 2018 for complicated urinary tract infections, including acute pyelonephritis, caused by susceptible Gram-negative bacteria. |
| Institute where first reported: | Achaogen Inc |
| Year first mentioned: | 2007 |
| Highest development stage: | Approved by FDA in 2018 |
| Development status: | Approved |
| External links: | |
| PubChem link: | https://pubchem.ncbi.nlm.nih.gov/compound/42613186 |
| Guide to Pharmacology: | plazomicin |
| Citations: |
|
| Patent: | WO2009067692A1 |